The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus

Diabetes Care

Volumn 27, Issue 10, 2004, Pages 2341-2347

  Lacy, Brian E ^a,d   Crowell, Michael D ^b   Schettler Duncan, Ann ^b   Mathis, Carole ^a   Pasricha, Pankaj J ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; DOMPERIDONE; ERYTHROMYCIN; INSULIN; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE MALEATE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEARTBURN; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LABORATORY TEST; MALE; NAUSEA AND VOMITING; PYLORUS; SATIETY; SIDE EFFECT; STOMACH ANTRUM; STOMACH EMPTYING; STOMACH PARESIS; STOMACH PRESSURE; WEIGHT GAIN;

ADULT; BOTULINUM TOXIN TYPE A; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GASTRIC EMPTYING; GASTROPARESIS; GASTROSCOPY; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MANOMETRY; MIDDLE AGED; PROBABILITY; PYLORUS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 4644301364     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.10.2341     Document Type: Article

References (26)

1. Koch K: Gastroparesis: diagnosis and management. Practical Gastroenterol 32:30-43, 1987
2. Horowitz M, Harding PE, Maddox A, Maddern GJ, Collins PJ, Chatterton BE, Wishart J, Shearman DJC: Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J Gastroenterol Hepatol 1:97-113, 1986
3. Rayner CK, Su YC, Doran SM, Jones KL, Malbert CH, Horowitz M: The stimulation of antral motility by erythromycin is attenuated by hyperglycemia. Am J Gastroenterol 95:2233-2241, 2000
4. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G: Erythromycin is a motilin receptor agonist. Am J Physiol 257:G470-G474, 1989
5. Anese V, Janssens J, Vantrappen G, Tack J, Peeters TL, Willemse P, Van Cutsem E: Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 102:823-828, 1992
6. Albibi R, McCallum RW: Metoclopramide: pharmacology and clinical application. Ann Int Med 98:86-95, 1983
7. Soykan I, Sarosiek I, McCallum RW: The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients wilh gastroparesis. Am J Gastroenterol 92:976-980, 1997
8. Kendall BJ, Kendall ET, Soykan I, McCallum RW: Cisapride in the long-lerm treatment of chronic gastroparesis: a 2-year open-label study. J Int Med Res 25:182-189, 1997
9. Mearin F, Camilleri M, Malagelada JR: Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 90:1919-1925, 1986
10. Lacy BE, Zayat EN, Crowell MD, Schuster MM: Botulinum toxin for the treatment of gastroparesis (Abstract). Gastroenterology 118:A624, 2000
11. Lacy BE, Zayat EN, Crowell MD, Schuster MM: Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 97:1548-1552, 2002
12. Lacy BE, Schettler-Duncan VA, Crowell MD: The treatment of diabetic gastroparesis with botulinum toxin (Abstract). Am J Gastroenterol 95:2455, 2000
13. Gupta P, Rao SSC: Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report. Gastrointest Endosc 56:104-107, 2002
14. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS: Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 55:920-923, 2002
15. Camilleri M, Hasler WL, Parkman HP, Quigley EMM, Soffer E: Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology 115:747-762, 1998
16. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kaloo AN: Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 332:774-778, 1995
17. Fishman VM, Parkman HP, Schiano TD, Hills C, Dabezies MA, Cohen S, Fisher RS, Miller LS: Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Am J Gastroenterol 91:1724-1730, 1996
18. NIH Consensus Development Conference Statement: Clinical use of botulinum toxin. Arch Neurol 48:1294-1298, 1991
19. Watkins CC, Sawa A, Jaffrey S: Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 106:373-384, 2000
20. Martinek J, Siroky M, Plottova Z, Bures J, Hep A, Spicak J: Treatments of patients with achalasia with botulinum toxin: a multicenter prospective cohort study. Dis Esophagus 16:204-209, 2003
21. D'Onofrio V, Miletto P, Leandro G, Iaquinto G: Long-term follow-up of achlasia patients treated with botulinum toxin. Dig Liver Dis 34:105-110, 2002
22. Neubrand M, Scheurlen C, Schepke M, Sauerbruch T: Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 34:519-523, 2002
23. Bansal R, Nostrant TT, Scheiman JM, Koshy S, Barnett JL, Elta GH, Chey WD: Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia. J Clin Gastroenterol 36:209-214, 2003
24. Richter JE: Comparison and cost analysis of different treatment strategies in achalasia. Gastrointest Endosc Clin N Am 11:359-370, 2001
25. Israel DM, Mahdi G, Hassall E: Pyloric balloon dilation for delayed gastric emptying in children. Can J Gastroenterol 15:723-727, 2001
26. Sun WM, Doran SM, Jones KL, Davidson G, Dent J, Horowitz M: Long-term effects of pyloromyotomy on pyloric motility and gastric emptying in humans. Am J Gastroenterol 95:92-100, 2000